Precision gene-editing for neurodegenerative diseases

Optimizing viral vector engineering for targeted gene delivery in neurodegenerative therapies

viral vectors gene therapy neurodegenerative diseases targeted delivery AAV optimization

**Through inflammasome inhibition: Novel approaches to combat chronic neurodegenerative diseases**

neuroinflammation NLRP3 inhibitors neurodegenerative therapies cytokine modulation blood-brain barrier

Through proteostasis network modulation to reverse age-related protein aggregation in neurons

proteostasis neurodegeneration aging protein aggregation drug discovery

With epigenetic reprogramming to reverse age-related cognitive decline

epigenetics aging cognitive decline neurodegeneration gene regulation

Targeting prion disease reversal with in-situ water ice utilization

prion disease ice nucleation protein misfolding neurodegenerative therapy cryobiology

Targeting protein misfolding in neurodegenerative diseases through proteostasis network modulation

protein misfolding proteostasis neurodegenerative diseases chaperone proteins amyloid aggregation

Enhancing synaptic vesicle recycling in neurodegenerative diseases using targeted kinase inhibitors

neurodegeneration synaptic vesicles kinase inhibitors vesicle recycling Alzheimer’s disease

Through inflammasome inhibition in neurodegenerative disease therapies

neuroinflammation NLRP3 cytokine release neurodegeneration therapeutic targets

Simulating prion disease reversal mechanisms via computational protein folding dynamics

prion disease protein folding computational biology neurodegenerative disorders molecular dynamics

Targeting protein misfolding in neurodegenerative diseases using carbon nanotube vias

protein misfolding carbon nanotubes neurodegenerative diseases biosensors amyloid fibrils

Optimizing gut-brain axis modulation via precision-engineered probiotic consortia for neurodegenerative disease mitigation

gut-brain axis probiotics neurodegenerative diseases microbiome engineering neuroinflammation

Targeting 2025 regulatory approval for CRISPR-based neurodegenerative therapies

CRISPR neurodegenerative diseases regulatory approval gene therapy clinical trials